You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

TRIGLIDE Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Triglide, and when can generic versions of Triglide launch?

Triglide is a drug marketed by Skyepharma Ag and is included in one NDA.

The generic ingredient in TRIGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-one suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Triglide

A generic version of TRIGLIDE was approved as fenofibrate by RHODES PHARMS on May 13th, 2005.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TRIGLIDE?
  • What are the global sales for TRIGLIDE?
  • What is Average Wholesale Price for TRIGLIDE?
Drug patent expirations by year for TRIGLIDE
Drug Prices for TRIGLIDE

See drug prices for TRIGLIDE

Drug Sales Revenue Trends for TRIGLIDE

See drug sales revenues for TRIGLIDE

Recent Clinical Trials for TRIGLIDE

Identify potential brand extensions & 505(b)(2) entrants

Medical University of South CarolinaPhase 4
Washington University School of MedicineN/A
Leducq FoundationN/A

See all TRIGLIDE clinical trials

US Patents and Regulatory Information for TRIGLIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-001 May 7, 2005 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-002 May 7, 2005 BX RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TRIGLIDE

See the table below for patents covering TRIGLIDE around the world.

Country Patent Number Title Estimated Expiration
Germany 60127457 ⤷  Sign Up
New Zealand 527408 Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia ⤷  Sign Up
Australia 2001259099 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 03092659 ⤷  Sign Up
European Patent Office 2228060 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.